In vitro susceptibilities of Entamoeba histolytica to azithromycin, CP-63,956, erythromycin, and metronidazole. |
| |
| Authors: | J I Ravdin and J Skilogiannis |
| |
| Affiliation: | Department of Medicine, University of Virginia School of Medicine, Charlottesville 22908. |
| |
| Abstract: | ![]()
Current therapy of Entamoeba histolytica infection requires use of multiple agents effective at different body sites, including the intestinal lumen, intestinal tissue, and liver. Azithromycin and CP-63,956, new extended-half-life macrolides which reach high levels in tissue, exhibit in vitro antiamebic activity at 18 or 48 h of incubation at concentrations comparable to that of erythromycin and slightly higher than that of metronidazole. Azithromycin and CP-63,956 have the potential to be useful therapeutic agents for all types of E. histolytica infection. |
| |
| Keywords: | |
|
|
